A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 4202 participants.
Also called NCT01703208
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 4,202 participants
- Sponsor
- Registry
-
NCT01703208 -
2012-002414-39
-
- Other papers using this trial's data
- A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Not reported
- Registry status
- Terminated
Technical summary
Registry record NCT01703208. Randomized; triple masking; primary purpose treatment. Start 2012-10-05 (actual); primary completion 2016-05-13 (actual). Results posted on 2017-12-12.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Omarigliptin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Merck Sharp & Dohme LLC
Record details
- Record id
cardio:ct-nct01703208- Content hash
2515ad2959309b3a13d46f28fe190e677da539d6d1287359eea24c93dbb01f51